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The Pharmacokinetics and Toxicology of Aluminum in the Brain
Robert A. Yokel*
Department of Pharmaceutical Sciences College of Pharmacy 511C Multidisciplinary Sciences Building 725 Rose Street
University of Kentucky Academic Medical Center Lexington, KY, 40536-0082
Abstract: The chemical forms (species) of aluminum in blood plasma and brain extracellular fluid are considered, as they
are the candidates for brain aluminum uptake and efflux. The blood-brain barrier is the primary site of brain aluminum uptake. The mechanism of brain uptake of aluminum transferrin, long thought to be mediated by transferrin-receptor mediated endocytosis, requires further investigation. Brain Al citrate uptake has been attributed to the sodium-independent Lglutamate/L-cystine exchanger system, system Xc-. Reports have suggested aluminum can compromise blood-brain barrier integrity, however the studies were conducted with aluminum concentrations greatly exceeding those seen in human blood
plasma. Aluminum appeared in cerebrospinal fluid suggesting it can cross the choroid plexus and in brain after intranasal application suggesting it can be taken up by cranial nerves, but neither of these routes has been definitively demonstrated. Brain
aluminum efflux appears to be carrier-mediated, however the mechanism has not been identified. A small increase in brain
aluminum seems sufficient to produce neurotoxicity. Once aluminum enters the brain it persists there for a very long time; estimates of the half-life range from 20% of the lifespan to greater than the lifespan. Al persistence in bone, which maintains the
majority of the body burden, may influence brain Al, due to equilibrium among the body’s organs. Chelation therapy with desferrioxamine has been shown to reduce some manifestations of aluminum toxicity although it may increase redistribution of
aluminum to the brain to increase aluminum-induced neurotoxicity. An orally-effective aluminum chelator that is an improvement over desferrioxamine has not yet been demonstrated. Although a non-essential metal, there are mechanisms enabling
aluminum to get into the brain, accumulating over the lifespan, and creating the potential to contribute to many neurodegenerative disorders.

Keywords: Aluminum, blood-brain barrier, brain efflux, brain influx, chelation, choroid plexus.
1. INTRODUCTION
Aluminum (Al) is not known to serve any essential function in the human, so one might consider its unintended
presence in the body as having potential risk and no benefit.
Its ability to produce neurotoxicity was demonstrated over
100 years ago [1]. Its potential to produce brain damage was
well illustrated with the onset of dialysis encephalopathy
(DES) during the onset of widespread hemodialysis. Some
dialysis patients exposed to Al in the dialysis fluid or from
receipt of oral Al-based phosphate binders developed a generalized brain dysfunction, leading to seizures and fatality
[2]. The safety of Al in the human has been controversial for
a century, including its use in cookware and food storage.
Further controversy developed when it was suggested Al
may be a neurotoxic factor in Alzheimer’s disease (AD) [3].
Owing to the recognition of Al as a neurotoxicant, it is beneficial to understand the mechanisms of brain entry and exit,
the residence time of Al in the brain, and factors that influence these endpoints, i.e., Al toxicokinetics. For humans
who develop neurobehavioral signs and symptoms due to
brain Al overload, or suspect they are suffering from Al intoxication, it is useful to know potential diagnostic and
treatment approaches to Al overload. This review focuses on
Al toxicokinetics in the brain and chelation therapy to diagnose and treat Al overload.
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2. THE CHEMICAL FORMS (SPECIES) OF ALUMINUM THAT MIGHT ENTER AND EXIT THE BRAIN
Aluminum can occur in various chemical forms (species)
in vivo, which have different physical, chemical and biological properties [4]. The toxicokinetics of Al is dependent on
its chemical species. Based on thermodynamic modeling,
and consistent with experimental observations, there are two
primary Al species in blood extracellular fluid (ECF), i.e.
plasma; Al transferrin (Tf) accounts for ~ 93% and Al citrate
~ 5.5% [5], making them the primary candidates for brain Al
uptake. Given the rapid formation of the 1:1 and 1:2
Al:citrate complexes and slow formation of the 1:3 complex
at the low Al concentrations of blood plasma [5], the Al citrate species in blood available to enter the brain might be the
1:1 and/or 1:2 complex.
The concentration of Tf is very low in cerebrospinal fluid
(CSF) (< 0.25 μM), and presumably brain ECF, compared to
30 μM in blood plasma [6]. Furthermore, it has been suggested that there are no available binding sites for Al on Tf
in brain ECF [7]. In contrast, the citrate concentration in
brain ECF is higher than in plasma (180 vs. 99 μM). CSF pH
is the same as blood plasma. These suggest that 90, 5, 4, and
1% of Al in CSF, and presumably brain ECF, is associated
with citrate, hydroxide, Tf, and phosphate, respectively, according to calculations conducted by Harris [8]. As Al citrate
is the predominant Al species in brain ECF, it is likely to be
the Al species transported into brain cells from CSF and
brain ECF or out of the brain.
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Because the free Al ion and its complexes with Tf and
citrate are quite hydrophilic (the octanol/aqueous distributions are 0.0052 and 0.0019, respectively), they would be
expected to diffuse across membranes such as the bloodbrain barrier (BBB) at a rate comparable to sucrose, which is
a very slow BBB permeant [9].
3. THE SITES AND RATES OF BRAIN ALUMINUM
UPTAKE
3.1. From the Blood Across the Blood-Brain Barrier
Al is most often absorbed from the gastrointestinal tract
or across the lungs into systemic circulation. Alternatively,
there is evidence some metals can be taken up by exposed
sensory nerves in the nasal cavity and possibly transported
into the brain, as discussed below.
Patients who received brain surgery for a tumor after
consuming an Al-rich antacid for 10 days had 2-fold higher
brain Al concentration than patients who consumed an antacid low in Al [10], demonstrating oral Al absorption and
distribution into the human brain in the presence of normal
renal function. This was supported by similar findings in
normal rats and rats with renal failure [11-14].
There are two routes by which Al might enter the brain
from blood, 1) through the BBB, and 2) through the choroid
plexus (CP) into the CSF of the ventricles within the brain
and then into the brain. Aluminum can rapidly enter brain
ECF and CSF, although its concentrations in these two fluids
are less than in blood [15-18]. To assess the primary route of
brain Al uptake, the flux of Al through the BBB and the CP
was assessed by concurrent microdialysis of the rat’s frontal
cortex, a lateral ventricle, and a jugular vein. This was conducted with an i.v. injection of Al citrate at a dose that exceeded the capacity of Tf to bind Al, therefore favoring Al
citrate as the Al species most likely to circulate in blood and
be available to enter the brain. Dialysate Al concentration
from the cortex peaked in the first 5 min sample and was
higher than from the lateral ventricle [15]. The rapid appearance of Al in the frontal cortex was attributed to brain Al
entry through the BBB rather than through the CP into CSF
and then diffusion into the brain. This was concluded based
on the following points: 1) the Al concentration was lower in
the CSF than in the frontal cortex, 2) Al diffusion from a
lateral ventricle into the brain would be against bulk CSF
flow within brain parenchyma to lateral ventricles [19], and
3) some frontal cortical regions in the rat are 1.5 mm from a
lateral ventricle and 1 mm from the subarachnoid space. This
distance was thought to be too great for Al to diffuse from
CSF to the frontal cortex within 5 min. The ~ 100- to 1000fold greater surface area of the BBB microvessels than the
vasculature perfusing the CP make the BBB the more likely
portal of brain Al entry. It was further concluded that Al entered the brain by a carrier-mediated process. The rate of Al
citrate flux through a membrane by diffusion was estimated
to be 4 x 10-16 mol cm-2 sec-1 [20]. Brain capillary surface
area has been estimated to be 240 cm2 /g brain [21]. Brain
ECF occupies ~ 15% of brain volume. The unbound plasma
Al concentration after the i.v. injection of Al citrate was estimated to be ~ 1 mM based on the Al concentration (~ 30
M) in the dialysate from microdialysis probes in the jugular
vein [15] and a relative recovery, using microdialysis, of Al
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from plasma ultrafiltrate of 3.25%. If 4 x 10-16 mole of Al
diffuses through 1 cm2 of membrane/sec, then ~ 3 x 10-11
mole of Al could diffuse through 240 cm2 of capillary endothelial cells into 1 gram of brain in 5 min. Assuming the latter amount of Al distributed throughout brain ECF, the Al
concentration would be ~ 2 x 10-17 M, producing a brain/
blood ratio of 0.0002. However, the brain/blood ratio seen 5
min after this i.v. injection of Al citrate was ~ 0.15 [15],
suggesting Al citrate brain uptake is carrier mediated.
The influx transfer coefficient (Kin) for Al has been reported in two non-peer-reviewed reports. For the free Al ion
it was reported to be ~ 1000 x 10-5 mL/sec/g; in the presence
of Tf, that would maximally bind 40% of the Al, it was ~
300 x 10-5 mL/sec/g [22]. In contrast, a much lower value (~
0.035 x 10-5 mL/sec/g) was reported in a second study,
which was based on quite variable results after a 50 h Al
perfusion [23]. The procedures used in both of these studies
may have underestimated Kin because they did not account
for potential brain Al efflux. The first utilized a 45 sec washout that followed brain Al perfusion. The second employed a
50 h infusion. The former values, when compared to the
brain capillary diffusion rate of sucrose (2.9 x 10-5 mL/sec/g)
[9], support the conclusion of carrier-mediated brain Al uptake.
Studies in which rats were i.v. or i.p. injected with Al
citrate, Al chloride or Al-Tf resulted in ~ 0.0008 to 0.009%
of the Al dose/g brain [15, 24-26]. These results show that
the extent of brain Al uptake is low. The percentage of the
dose of Al injected s.c. into pregnant rats on gestation day 15
was 0.0067 and 0.0002% in maternal and fetal brain, respectively, 5 days later [27], demonstrating the ability of Al to cross
the placenta and fetal BBB.
4. THE MECHANISMS OF BRAIN ALUMINUM UPTAKE
The barrier properties of the BBB are primarily attributed
to the tight junctions between opposing plasma membranes
of the endothelial cells that comprise the microvessels that
perfuse the brain, greatly limiting paracellular diffusion [28].
Contributing to this barrier are two additional properties of
these endothelial cells; 1) the nearly total absence of fenestrations through which substances might diffuse and 2) the
low rates of fluid phase endocytosis that might engulf Al in
the blood and internalize it. Further membrane barriers are
provided by the following; (i) a basement membrane that
surrounds the brain microvascular endothelial cells
(BMECs), (ii) pericytes that surround ~ 30% of the endothelial abluminal cell surface, and (iii) astrocyte foot processes
that cover > 90% of the surface of the endothelial cells and
pericytes [29]. The BMECs are extensively distributed
throughout the brain, so that every brain cell is within ~ 30 to
50 m of a blood supply, providing very rapid exchange of
substances between blood and brain cells (Arnold Scheibel,
personal communication). This anatomy can be seen in many
of the figures of the human cerebellum published by Duvernoy et al. [30] and in mouse cortex (Fig. 2B of [31]).
Mechanisms of brain uptake include diffusion and carrier
mediated transport. As noted above, paracellular diffusion
through the BBB is greatly limited, if not prevented. Diffusion through BBB membranes greatly decreases as size ex-
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ceeds ~ 400 daltons and favors lipophilic substances [31].
Many transporters are expressed at the BBB [31]. Some mediate brain uptake, others prevent brain uptake, and some are
bidirectional. Some are equilibrative. Some are energydependent that are able to move substrates unidirectionally
and against a concentration gradient. There are receptormediated mechanisms which may operate by facilitated diffusion and are often bidirectional [31]. An example of metal
species-specific transport at the BBB is the large neutral
amino acid transporter that facilitates brain influx of the
methylmercury L-cysteine complex, which is perhaps mistaken for the structurally similar L-methionine [32].
The Al-Tf complex was shown to bind to (be taken up
by) IMR 32 and C1300 neuroblastoma cells with an equilibrium constant and uptake half-life (t) similar to the iron
(Fe)-Tf complex [33, 34]. Uptake of Al following Al-Tf exposure has been shown with non-CNS cells, and was generally greater than from Al citrate [35-41]. Using whole brain
homogenate, the binding of Al-Tf was shown to have a
lower affinity than Fe-Tf, but was quite high, leading the
authors to suggest Tf and its receptor may enable brain Al
access [42]. Oligodendrocytes took up more Al as Al-Tf than
Al citrate or the Al ion (introduced as the chloride) [43].
These results suggested Al might enter the brain via transferrin-receptor mediated endocytosis (TfR-ME).
Based on the rate of TfR-ME of Fe into the brain (Kin =
0.08 x 10-5 mL/sec/g), the blood Al concentration from its
injection to the time of brain harvest, and assuming that AlTf was cleared from blood to brain over the four h by a first
order process, TfR-ME could account for the observed brain
influx of Al (above). The contribution of TfR-ME to brain Al
uptake is consistent with the positive correlation between Al
concentration in cortical and hippocampal neurons and the density of TfRs [44]. However, the affinity of TfR 1 for the Al-Tf
complex was found to be very weak in vitro, leading Hémadi
et al. to caution that Al transfer from blood to cell cytoplasm
may not follow the TfR-ME pathway [45]. In another report
from the same laboratory Ha-Duong et al. found no interaction between Al-Tf and the TfR [46]. Based on structural and
physicochemical characteristics of apo-Tf, Fe-Tf, Al-Tf and
the TfR (diffusion coefficient, hydrodynamic radius, capillary electrophoretic mobility, and zeta potential) and calculation of acidic amino acid residues, Sakajiri et al. concluded
that the driving force for the formation of a complex of metal
and the TfR is the electrostatic interaction between the negative charge of the former and positive charge of the latter.
Because the Al-Tf complex surface charge is nearly the same
as apo-Tf, and less negative than Fe-Tf, they suggested formation of an Al-Tf and TfR complex is not possible [47].
Several groups have reported that Al-Tf reduces brain Fe
uptake. Studies to elucidate the mechanism of this found that
the Al-Tf complex reduced the level of TfR mRNA in human erythroleukemia (K562) cells and the density of surface
Tf binding sites on oligodendrocytes [35, 43]. However, a
more recent report failed to find an effect of Al-Tf on TfR
mRNA levels, TfR surface antigenic sites, or total TfR
(membrane plus cytoplasm) quantity [41]. The latter results
suggested Al-Tf was acting on sites other than the TfR to
modulate Fe uptake. Therefore, it appears that the long held
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assumption that TfR-ME plays a role in mediating brain Al
uptake may not be true. This requires further investigation.
There is evidence for a mechanism transporting Al citrate
across the BBB. Brain Al uptake in the presence of Tf was
lower than in its absence [22]. There was a lack of significant difference in brain Al uptake in hypotransferrinemic vs.
control mice and after treatment with a TfR antibody in mice
infused with Al citrate [48].
Given that the coordination binding of Al to citrate involves two carboxylates and the hydroxyl group, leaving a
terminal carboxylate group unbound at physiological pH [49,
50], it was hypothesized that the monocarboxylate transporter
(MCT) mediates Al citrate distribution across the BBB. Introduction of 2,4-dinitrophenol (a metabolic inhibitor), pyruvate (a competitive substrate for the MCT), mersalyl (an MCT
inhibitor), carbonyl cyanide p-trifluoromethoxyphenyl-hydrazone (FCCP, a proton ionophore that should reduce the proton
gradient required by the MCT for substrate transport), and a
decrease of proton availability on the brain side of the BBB
all produced results consistent with the hypothesis [51, 52]. To
further assess the hypothesis studies were conducted with rat
erythrocytes, which express MCT-1 and the anion exchanger.
The results did not show significant uptake of Al citrate into
erythrocytes [53]. To investigate the properties of the carrier
mediating Al citrate brain uptake, studies were conducted
with an immortalized murine BBB endothelial cell line. The
results suggested Al citrate uptake was energy dependent,
ATP- but not Na/K-ATPase-dependent, and not a substrate for
a dicarboxylate carrier or the -ketoglutarate exchanger. Its
uptake was inhibited by numerous compounds, most of
which are MCT substrates or inhibitors [53]. These results
and the properties of the organic anion transporting polypeptide (oatp) family suggested it as a candidate. Al citrate
weakly inhibited the uptake of an organic anion transported
substrate in oocytes expressing rOAT3, suggesting it may be
a substrate of an organic anion transporter (B. Feng, K.M.
Giacomini & Yokel, unpublished observations).
Magnesium D-aspartate was found to reduce brain Al
accumulation following Al L-glutamate administration [54].
As D-aspartate is a substrate for glutamate transporters, it
was suggested that it might cause the counter-transport of Al
citrate. Investigating this hypothesis it was found that Al
citrate uptake into an immortalized rat BBB endothelial cell
line was inhibited by ligands for the sodium-independent Lglutamate/L-cystine exchanger system Xc-. Aluminum citrate
uptake was increased into cells loaded with these ligands, suggesting a trans-stimulatory effect. These results suggest that
system Xc- may mediate Al citrate uptake into the brain across
the BBB [55].
5. THE EFFECTS OF ALUMINUM ON THE BLOODBRAIN BARRIER
There have been many studies assessing the potential of
Al to compromise BBB function. Most were conducted utilizing conditions and Al concentrations that are not relevant
to humans. Following the i.p. injection of Al chloride or Al
lactate, often 100 mg Al/kg or greater, the brain concentration of BBB markers increased [56-60]. This dose is 1000-

The Pharmacokinetics and Toxicology of Aluminum in the Brain

fold greater than the average daily oral Al intake by humans.
Considering that oral Al bioavailability is ~ 0.3% and assuming
100% absorption of Al from the peritoneal cavity during this
time, this dose would be expected to produce blood Al levels
that far exceed those relevant to typical Al intake by humans.
In vivo studies with bovine BMECs suggested Al interacts
with the cell membrane surface [61]. Acellular studies suggested Al perturbation of membrane structure, perhaps due
to its competition for Ca binding, production of vesicle fusion, and membrane rigidification [62].
The i.p. injection of 100 mg Al/kg (as chloride) resulted
in a dose-dependent increase of brain uptake of 125I-N-Tyrdelta-sleep-inducing peptide and 125I--endorphin 1 and 2 h
later [63, 64]. Efflux of the 125I-labelled proteins Tyr-MIF
(Tyr-Pro-Leu-Gly-amide) and enkephalins from the brain
after their intracerebroventricular injection was inhibited by
i.p. injection of Al 100 mg Al/kg (as chloride), whereas efflux of technetium pertechnetate, albumin and D-Tyr-MIF-1
was not [65]. Reviewing their results, Banks and Kastin concluded that Al increased transmembrane diffusion and selectively altered saturable transport systems [66]. Subcutaneous
injection of 100 μg Al/kg (as chloride hexahydrate) reduced
brain influx and efflux of quinidine (a cation) and reduced
aspirin (an anion) efflux from the brain without affecting its
influx [67]. Studies exposing goat BMECs to Al at a concentration at least 10-fold greater than the threshold for clinical
concern [68] produced alterations in the biophysical and biochemical properties of the BBB. These results suggest Al
could alter flux of agents across the BBB, disrupting brain
chemistry. However, considering the very large dose of Al
used in these studies, the relevance of the findings to human
exposure is questionable.
6. FROM THE BLOOD ACROSS THE CHOROID
PLEXUS
6.1. The Choroid Plexus and its Transporters
There is a CP in each of the two lateral, the third, and the
fourth ventricles of the brain. They have a monolayer of
epithelial cells that, like the BBB, have tight junctions, and
express many carriers. They are the sites of production of
most of the CSF. Substances that cross the CP from blood
enter the CSF. The ability of Al to distribute into the CSF
from blood was demonstrated by the presence of measurable
Al in CSF within 30 min after its i.v. injection as either the
chloride or sulfate salt [17, 69]. However, as brain ECF Al
concentration was greater than CSF Al concentration following i.v. Al administration [15], and a source of CSF is brain
ECF, it is possible that the Al seen in the CSF crossed the
BBB rather than the CP. There are no peer-reviewed reports
assessing the extent, rate, or mechanism of Al flux across the
CP that lack the confounding factor of flux across the BBB.
The CSF Al concentration was reported to be < 1 to 6
μg/L in normal humans and those with Parkinson’s disease
and AD, and somewhat higher (3 and 7 μg/L) in three Alintoxicated dialysis patients [6, 70-72]. The Al appeared to
be associated with citrate. As the Al concentration in serum
was ~ 25-fold higher than in CSF, it appears that the CP does
not allow free Al flux.
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7. ALUMINUM UPTAKE FROM THE NASAL CAVITY
7.1. Brain Aluminum Entry via the Olfactory and Trigeminal Neurons
The roof of the nasal cavity is the only site where the
nervous system is directly exposed to the environment, as
terminals of the olfactory and sensory branch of the trigeminal nerves. Uptake from the nasal cavity into the olfactory
nerve, followed by retrograde axonal transport to the olfactory bulb and beyond, was shown in studies of the polio virus, colloidal silver-coated gold, manganese, rubidium, thallium, yttrium, perhaps nickel, ~ 35-nm 13C particles, and ~
30 nm agglomerates of manganese, and may occur for other
metals [73-81]. The anatomy of this process was reviewed
[82]. The olfactory neurons project into the mucus that covers the olfactory epithelial surface, enlarging into an olfactory knob that has ciliary extensions (the sites of odor receptors) and extensive endocytotic vesicles. Exogenous substances might be taken up from the nasal cavity by the odor
receptors or by endocytosis. Olfactory nerve axons can
transport, by retrograde axonal transport, substances to the
olfactory bulb, where they synapse with mitral and tufted
cells, the secondary olfactory neurons. These latter cells can
transport substances to the olfactory cortex, where they synapse on pyramidal cells, the tertiary olfactory neurons. Pyramidal cells have synaptic connections with pathways to
multiple cortical and subcortical regions. These neuronal
pathways provide a mechanism for distribution to multiple
brain regions of exogenous substances that are able to cross
synapses. Manganese uptake by the sensory branch of the
trigeminal nerve within the nasal cavity has also been described [83]. Some of the distribution into the brain may
have occurred by routes other than via the cranial nerves,
such as through CSF or across the BBB. Although this route
of uptake appears to deliver a very small percentage of drug
or metal to the brain, it could be significant over a lifetime
[78, 84]. There is the potential for Al uptake via this route,
however most airborne Al is in Al silicates which contain
very little ionic, exchangeable Al [85].
To assess whether Al can enter the brain from the nasal
cavity, Gelfoam® containing 0.5 mL of 15% Al lactate, 5%
Al chloride, or 15% sodium lactate was implanted for one
month into the nasal recess of rabbits [86]. Elevated Al and
neuropathological changes were seen in the olfactory bulb,
piriform cortex, hippocampus and cerebral cortex, but not in
cerebellum, brainstem or spinal cord. These results suggested Al uptake from the nasal cavity and Al-induced pathology in pathways connected to the olfactory tract. However, concern was raised about the possibility that this prolonged exposure mechanically disrupted the olfactory epithelia [87]. Al uptake and granulomas in the piriform cortex,
basal forebrain, hippocampus, and neocortex were also reported from a 75 mM suspension of a lipophilic Al flavonol
complex placed in the nasal cavity of the rabbit [88]. Compared to the typical urban air concentration of 1 μg Al/m3 and
inhalation of 20 m3/day which is not necessarily all delivered
through the nose and which is composed mostly of insoluble
Al silicates, one must question the physiological relevance of
this route of Al exposure. To further assess the possibility
that Al can enter the brain from the nasal cavity, rats were
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nose-only exposed to aerosolized Al chlorohydrate and brain
Al assessed [89]. A significantly greater Al concentration in
the olfactory bulb was seen than in non-olfactory brain regions. Rats exposed to lipophilic Al acetylacetonate under
conditions designed to maximize inhalation via the nasalolfactory system showed increased brain Al in the olfactory
bulb, cortex, hippocampus, and entorhinal area. Elevated Al
was also seen in the cerebellum, a structure which is not
within, or directly connected neuronally to, the olfactory
pathway [90], These data suggested that Al may have diffused through the CSF, rather than being transported through
neurons.
7.2. Brain Entry from the Nasal Cavity via the CSF Surrounding Cranial Neurons
A second potential route of Al uptake from the nasal cavity is via the CSF in the perineural space surrounding the
olfactory nerve. This has also been postulated as a route of
brain prion uptake [91]. Aluminum diffusion by this route
would be expected to initially result in distribution into CSF
in the subarachnoid space and over the cortical surface.
8. BRAIN ALUMINUM EFFLUX
Evidence suggesting an Al efflux mechanism at the BBB
was provided from results of studies in which Al was i.v.
infused for sufficient time to achieve steady state Al concentrations in blood and brain ECF. An eight-fold range of infusion rates was used. The ratio of Al in the brain compared to
the blood was ~ 0.15. If diffusion mediated transmembrane
Al flux, then, (Al clearance into the brain from blood) x (Al
unbound concentration in blood ECF) should equal (Al
clearance out of the brain) x (Al unbound concentration in
brain ECF). As this ratio was much less than 1, it suggested
that Al clearance out was greater than the clearance in, leading to the conclusion that brain Al efflux is mediated by a
process other than diffusion [16]. The mechanism(s) mediating brain Al efflux has not been identified.
9. BRAIN ALUMINUM CONCENTRATION AND DISTRIBUTION
The concentration of Al in the brain is much lower than
many other tissues, even in the presence of overt neurotoxicity. Increased brain Al concentrations of ~ 4- to 6-fold in
rabbits and somewhat higher increases in humans suffering
from DES were associated with neurotoxicity [92-94]. Brain
Al concentrations in victims of Creutzfeld-Jakob disease were
not different from controls. As this neurodegenerative disorder
is associated with widespread neuronal and glial pathology, it
was concluded that brain damage alone does not result in elevated brain Al [95]. Similarly, brain Al was not elevated in 20
patients who died from liver disease or other complications of
chronic alcoholism [96].
Based on a literature review of Al concentration in various brain regions Speziali and Orvini concluded that Al is
generally higher in grey than white matter [97]. Using the
Morin method to visualize Al, a positive fluorescence signal
was detected in disintegrating neurofibrillary tangles and the
senile plaque amyloid cores of non-demented elderly subjects. It was also seen in the wall of the capillary vessels of

Robert A. Yokel

the BBB, perivascular glial supporting tissues, nuclei of astrocytes, and nuclei and nucleoli of neurons in normal brain
tissue [98].
10. BRAIN ALUMINUM RESIDENCE TIME
Most studies have reported a positive correlation between
brain Al concentration and age [98-105]. This increase could
be due to increased exposure with age, an increasingly leaky
BBB with ageing, a decreased ability to remove Al from the
brain with age (i.e., due to age-associated impaired kidney
function), or very slow, or no, elimination of brain Al.
The rate of Al elimination from the entire organism may
drive the rate of Al clearance from the brain, owing to the
expected equilibrium among the compartments of Al storage.
The skeletal system is the major compartment of Al storage,
containing ~ 58% of the human Al body burden [106].
Aluminum persists for a very long time in rat brain following systemic injection of very small doses of 26Al. Rat
brain 26Al increased slightly from days 5 to 35 after an i.p.
26
Al injection [24], suggesting a lack of brain Al elimination.
However, the possibility of 26Al precipitation and delayed
absorption from the peritoneal cavity, the small number of
subjects, and the lack of a non-26Al dosed group to control
for cross-contamination undermine confidence in these results. A subsequent study found no decrease in brain 26Al
concentration up to 270 days after 26Al injection [107].
When 26Al was given i.v. to rats that were euthanatized up to
256 days later, the t of brain Al was estimated to be ~ 150
days [26]. Offspring of rats that were given 26Al injections
daily from day 1 to 20 postpartum were weaned on day 20
and sacrificed up to 730 days postpartum. Aluminum concentrations decreased over the 730 days in all tissues. At
postpartum day 730, brain 26Al had decreased to ~ 15% of
that seen at weaning (day 20 postpartum) [108]. Calculation
of the elimination ts by the author of this review suggested
they were ~ 13 and 1635 days in brain. There is little published information on allometric scaling of metal elimination
rates that could be used to extrapolate these results from the
rat to the human. 150 days is ~ 20% of, and 1365 days exceeds, the rat’s normal life span. For comparison, the wholebody t of Al in the human was estimated to be 50 years
[109]. As brain Al was not determined for at least 3 ts in the
animal studies and the estimated whole-body t of Al in the
human is well beyond the study period, these estimated terminal ts of brain Al are not expected to have a high degree
of accuracy.
11. CHELATION OF BRAIN ALUMINUM
In initial uncontrolled studies, desferrioxamine (DFO)
was given to patients with DES. DFO mobilized Al from
storage sites into blood, increased Al elimination, and reversed some DES symptoms [110, 111]. Further clinical
studies showed that DFO can reduce DES mortality [112].
DFO administered to a few AD patients for > three months
was claimed to significantly reduce brain Al when compared
to a few non-DFO-treated subjects [113]. To assess the potential for DFO to benefit patients with AD, 25 probable AD
patients were given 125 mg (0.19 mmol) DFO i.m. twice
daily five days weekly for two years [114]. The control
groups of probable AD patients received oral lecithin or no
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treatment. A lower mortality and a slower rate of deterioration of activities of daily living were seen in the DFO-treated
group. Average cortical brain Al at autopsy in three humans
with AD treated with a higher dose of DFO was lower than
three AD subjects who received a lower dose, suggesting
that DFO-mobilization of Al from the brain might have contributed to the beneficial effects in these patients [115]. Further studies are necessary to confirm these results and to determine if the beneficial effect of DFO is mediated by Al
and/or Fe chelation, by reduction of oxidative injury, or via
some other mechanism.
In animal studies, twice daily i.m. DFO injections considerably reduced the brain Al concentration in rabbits that
were given intracisternal Al maltolate injections [116]. Repeated i.p. DFO injections to rats that had been given a single i.v. Al injection reduced the brain Al t from ~ 150 to ~
55 days [26]. These animal studies demonstrate the ability of
DFO to accelerate Al clearance from the brain. It is not
known if DFO enters the brain to chelate and reduce brain Al
or if the reduction of brain Al is due to peripheral Al chelation causing redistribution of Al out of the brain.
There are numerous reports of the onset or exacerbation
of encephalopathy and seizures during or shortly after dialysis in Al-loaded humans whose Al accumulation was treated
with DFO [117-127]. These adverse effects have been attributed to DFO and to Al mobilization by DFO. Al in CSF increased in a patient whose DES worsened after DFO [126].
To determine if DFO therapy can cause a redistribution of Al
to the brain, non-protein bound Al in brain, liver, and blood
ECF was measured in Al-loaded rats after DFO administration. DFO rapidly increased free Al in the liver, suggesting
that it mobilized hepatocyte Al and formed an Al:DFO complex, aluminoxamine. An increase in brain ECF Al was also
seen which could have been due to chelation of brain Al or
distribution of the Al complexed from the liver into the brain
[128]. The efficacy of a low-dose DFO therapeutic regimen
has been shown [129].
As DFO is ineffective orally and has significant clinical
toxicity, there has been a decades-long search for an orally
effective Fe (and Al) chelator. Two orally-absorbed hydroxypyridinone chelators (deferiprone [termed L1 & CP20]
and CP94), which were developed to overcome the lack of
oral absorption of DFO, decreased brain Al after i.p. injection [130]. However, little change of brain free Al concentration was seen in Al-loaded rats after injection of these and
two other hydroxypyridinone chelators [131]. Repeated oral
administration of six hydroxypyridinone chelators to Alloaded rabbits increased Al elimination, primarily in the
urine, and decreased blood Al levels. A few of these chelators increased CSF Al, but only one (CP-24) significantly
decreased brain Al concentration [132]. A substituted
pyrimidine given by gavage was found to reduce brain Al in
Al-loaded mice, although not as effectively as i.p. DFO, providing some hope of the ability to synthesize an orally effective
Al chelator [133].
There has been little study of combined therapies to reduce brain Al. Using Al-loaded human brain cell nuclei, the
ability of concurrent addition of various chelators to mobilize Al was assessed. Combined ascorbate and Feralex-G (a
maltol, glycine and glucosamine complex) was found to be
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effective, leading the authors to suggest that ascorbate penetrated the nucleus to complex Al, followed by diffusion of
the Al complex to regions where it could be accessed by
larger chelators [134]. Oral administration of glutathione
paired with Tiron given i.p. reduced oxidative stress in the
brain to a greater extent than Tiron alone, but the combination did not enhance the ability of Tiron to reduce brain Al
[135]. Five consecutive daily i.p. injections of N-(2hydroxyethyl) ethylenediaminetriacetic acid (HEDTA) to Alloaded rats significantly reduced blood and brain Al nearly
to control rat levels, but the addition of oral citrate did not
further decrease Al levels [136].
12. CONCLUSION
In summary, there is evidence for transporter-mediated
influx and efflux of Al across the BBB, the primary site of
brain Al uptake. The glutamate transporter system Xc- has
been suggested to mediate brain Al citrate uptake. The role of
Al-Tf in brain Al uptake and the underlying mechanism(s)
require further research to understand. There is also evidence
for carrier-mediated Al efflux from the brain, however, the
mechanism(s) have not yet been identified. Identification of
the mediating process(es) and factors that influence it (them)
might provide insight into ways to reduce the brain’s Al burden. It appears that Al persists in the brain for a long time
[with t estimates of 20% of, to beyond, the lifespan], and
accumulates over the lifespan, creating the potential to contribute to neurodegenerative disorders. As this is of concern,
ways to avoid this would be valuable to understand. Chelation therapy can reduce some of the effects of Al toxicity,
probably in the presence of profound Al intoxication. However, chelating agents also appear to have the potential to
enhance Al-mediated neurotoxicity due to redistribution of
the Al-chelator complex. A better understanding of the factors that impact on the redistribution of the Al-chelator complex to the brain, and identification of chelators that have
less or no risk to do this would be valuable. It would be
highly desirable to resolve the contentious controversy of the
role of, or lack of, Al as a contributing factor in AD.
13. ABBREVIATIONS
AD

=

Alzheimer’s disease

Al

=

Aluminum

BBB

=

Blood-brain barrier

BMEC

=

Brain microvascular endothelial cell

CP

=

Choroid plexus

CSF

=

Cerebrospinal fluid

DES

=

Dialysis encephalopathy syndrome

DFO

=

Desferrioxamine

ECF

=

Extracellular fluid

Kin

=

Influx transfer coefficient

MCT

=

Monocarboxylate transporter

Tf

=

Transferrin

TfR

=

Transferrin-receptor

TfR-ME

=

Transferrin-receptor mediated endocytosis
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